Overview

AZD9773 Dose Escalation Study

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled, multi-center, dose-escalation study to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single and multiple ascending intravenous infusions of CytoFab (AZD9773) in adult patients with severe sepsis.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca